Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Breast Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00001498

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Neoplasms
Metastases, Neoplasm

First Posted Date: 2002-11-11

Last Posted Date: 2012-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00048893

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: F-18 Fluorodeoxyglucose
Biological: therapeutic allogeneic lymphocytes
Procedure: Peripheral Blood Stem Cell donation
Drug: cyclophosphamide
Drug: cyclosporine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Drug: prednisone
Drug: sirolimus
Drug: tacrolimus
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation
Drug: Filgrastim

First Posted Date: 2002-08-16

Last Posted Date: 2017-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00043979

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

Phase 1

Completed

Conditions: Metastases, Neoplasm
Pancreatic Neoplasms
Colorectal Neoplasms
Esophageal Neoplasms
Liver Neoplasms
Cholangiocarcinoma
Stomach Neoplasms
Breast Neoplasms
Melanoma
Sarcoma

First Posted Date: 2002-07-19

Last Posted Date: 2005-06-24

Lead Sponsor: FeRx

Target Recruit Count: 20

Registration Number: NCT00041808

Locations: 🇩🇪
Frankfurt Universtiy, Frankfurt, Germany
🇺🇸
Scripps Stevens Cancer Division, San Diego, California, United States
🇺🇸
Scott and White Clinic, Temple, Texas, United States

and more 1 locations

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Imatinib Mesylate
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Dexamethasone
Drug: Methotrexate
Drug: Cytarabine
Drug: Mesna
Drug: G-CSF

First Posted Date: 2002-06-04

Last Posted Date: 2015-09-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT00038610

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Phase 3

Completed

Conditions: Hodgkin Disease

Interventions: Drug: Filgrastim SD/01
Drug: Adriamycin
Drug: Bleomycin
Drug: Vinblastine
Drug: DTIC

First Posted Date: 2002-06-03

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00038558

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients

Phase 2

Terminated

Conditions: Ewing's Sarcoma

Interventions: Drug: Vincristine
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Dexrazoxane
Biological: ImmTher

First Posted Date: 2002-05-30

Last Posted Date: 2020-01-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00038142

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer

Phase 2

Terminated

Conditions: Carcinoma, Hepatocellular

First Posted Date: 2002-04-26

Last Posted Date: 2005-06-24

Lead Sponsor: FeRx

Target Recruit Count: 240

Registration Number: NCT00034333

Locations: 🇷🇺
Central Research Institute of Roentgenology and Radiology, Pesochny, St. Petersburg, Russian Federation
🇹🇭
National Cancer Institute, Bangkok, Thailand
🇺🇸
Scott & White Mem. Hosp. & Clinic, Temple, Texas, United States

and more 26 locations

A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.

Phase 3

Completed

Conditions: Sarcoma, Kaposi
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Nexstar Pharmaceuticals

Registration Number: NCT00002093

Locations: 🇺🇸
Kenneth Norris Jr Cancer Hosp, Los Angeles, California, United States
🇺🇸
Dr Edward Stool, Houston, Texas, United States
🇺🇸
Univ of Miami Dept of Medicine, Miami, Florida, United States

and more 10 locations

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

Phase 3

Conditions: Sarcoma, Kaposi
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Sequus Pharmaceuticals

Target Recruit Count: 225

Registration Number: NCT00002318

Locations: 🇺🇸
Dr Mahmoud Mustafa, Washington, District of Columbia, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States

and more 23 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy